Crossmark

Iatrogenic cerebral amyloid angiopathy and cerebral amyloid angiopathy-related inflammation: clinical, radiological and biological findings from a case

Crossref DOI link: https://doi.org/10.1007/s10072-025-08695-6

Published Online: 2025-12-27

Published Print: 2026-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Avola, Giulia

Bottignole, Dario

Cancilla, Rita

Florindo, Irene

Lucia, Davide D.

Grisafi, Elena

Cerasti, Davide

Scarlattei, Maura

Piazza, Fabrizio

Menozzi, Roberto

Ruffini, Livia

Pezzini, Alessandro https://orcid.org/0000-0001-8629-3315
License Information

Text and Data Mining valid from 2025-12-27

Version of Record valid from 2025-12-27
More Information

Article History

Received: 22 July 2025

Accepted: 21 October 2025

First Online: 27 December 2025

Declarations

:

: The UNIMIB Institutional Ethical Committee on human experimentations approved the study (biomarkARIA protocol #268/02112016 and modelCAA protocol #372/16042018). All patients provided written informed consent for the use of clinical, laboratory, and imaging data.

: Written informed consent was obtained from the patient for participate of this report.

: FP: Consulting services and educational activities, paid to the University of Milano Bicocca, with Alnylam Pharmaceuticals, Roche, Biogen, Alector, Lilly, Araclon. Inventor, without ownership, of the amyloid-beta antibody assay. The other authors declare no conflicts of interest.

Document is current

Any future updates will be listed below